Results 221 to 230 of about 126,909 (281)

Comprehensive improvement in cardiac function following myosin inhibition after the ineffectiveness of myectomy and alcohol septal ablation: a case report. [PDF]

Eur Heart J Case Rep
Aleksandrov A, Haverkamp W, Borges AC, Zöller T, Knebel F.   +4 more
europepmc   +1 more source

Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model. [PDF]

Eur Heart J
Baka T, Moore J, Qin F, Yurista SR, Zhang A, He H, Chambers JM, Croteau D, Goel RK, Smith H, Wang MC, Chen CS, Hobai IA, Rombaldova M, Kuda O, Tardiff JC, Balschi JA, Pimentel DR, Seidman CE, Seidman JG, Emili A, Colucci WS, Luptak I.   +22 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management

Annals of Pharmacotherapy, 2023
Objective: To review the current literature on the efficacy and safety of cardiac myosin inhibitors (CMIs) for the treatment of hypertrophic cardiomyopathy (HCM).
Alyssa Sykuta, Connie H. Yoon, Sarah Baldwin, Natalie I. Rine, Michael Young, Adam Smith   +5 more
semanticscholar   +3 more sources

Monitoring treatment with cardiac myosin inhibitors in symptomatic obstructive hypertrophic cardiomyopathy

Current Opinion in Cardiology, 2023
Purpose of review Cardiac myosin inhibitors (CMIs) represent a major milestone in the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy.
S. Chatur, Sheila M. Hegde
semanticscholar   +3 more sources

Advances in Cardiovascular Pharmacotherapy. I. Cardiac Myosin Inhibitors.

Journal of Cardiothoracic and Vascular Anesthesia
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy. The disease is characterized by asymmetric left ventricular (LV) remodeling with myocyte disarray and interstitial fibrosis, a hypercontractile state, dynamic subaortic ...
P. Pagel, Dustin Hang, Julie K. Freed, G. J. Crystal   +3 more
semanticscholar   +3 more sources

Aficamten—A Second in Class Cardiac Myosin Inhibitor for Hypertrophic Cardiomyopathy

Cardiology in Review, 2023
Hypertrophic cardiomyopathy is an under-recognized disease with a genetic component that results in abnormal and often asymmetric thickening of the left ventricle in addition to decreased compliance and progressive fibrosis of the myocardium.
Jay Patel, An-ning Wang, Srihari S. Naidu, William H. Frishman, W. Aronow   +4 more
semanticscholar   +3 more sources

Heart of the matter: A GP’s guide to cardiac myosin inhibitors

InnovAiT: Education and inspiration for general practice
Hypertrophic obstructive cardiomyopathy (HOCM) is a heritable heart condition. It causes hypertrophy of the heart muscle and left ventricular outflow tract obstruction.
Tamara Naneishvili, W. J. How, Ivo Andrade, Samantha Cummins, David Hutchings, Aneil Malhotra, Luigi Venetucci, Rhys Beynon, Andrew Michael Crean   +8 more
semanticscholar   +2 more sources

Novel Selective Cardiac Myosin-Targeted Inhibitors Alleviate Myocardial Ischaemia–Reperfusion Injury

Cardiovascular Drugs and Therapy
Reperfusion of the ischaemic heart is essential to limit myocardial infarction. However, reperfusion can cause cardiomyocyte hypercontracture. Recently, cardiac myosin-targeted inhibitors (CMIs), such as Mavacamten (MYK-461) and Aficamten (CK-274), have ...
Nur Liyana Mohammed Yusof, D. Yellon, S. M. Davidson   +2 more
semanticscholar   +3 more sources